Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies
Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies. Cancer 2008, 112: 2710-2719. PMID: 18481809, DOI: 10.1002/cncr.23442.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Squamous CellCetuximabCisplatinClinical Trials as TopicDrug Resistance, NeoplasmHead and Neck NeoplasmsHumansMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsMetastatic squamous cell carcinomaSquamous cell carcinomaMetastatic SCCHNPlatinum therapyRetrospective studyCell carcinomaEpidermal growth factor receptor (EGFR) inhibitor cetuximabActivity of cetuximabCarboplatin-based chemotherapyCetuximab-based treatmentCisplatin/carboplatinDisease control rateMedian overall survivalSecond-line therapySecond-line treatmentEfficacy of cetuximabPlatinum-based therapyOverall response ratePlatinum failureOverall survivalMedian timeProlong survivalProspective studyControl rateEfficacy data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply